Michael Casey, MD
Nephrology · Raleigh, NCNPI 1003894056
Payments from drug & device makers
Across 347 payments — averaging $1611.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$324K
- Alnylam Pharmaceuticals Inc.$78K
- Akebia Therapeutics Inc$65K
- Travere Therapeutics, Inc.$45K
- Hoffmann-la Roche Limited$28K
- Astrazeneca UK Limited$13K
- plus $6K from 22 others
Across 7 payments — averaging $141.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$993
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 64 | $323,746 |
| Alnylam Pharmaceuticals Inc. | 9 | $77,929 |
| Akebia Therapeutics Inc | 82 | $65,062 |
| Travere Therapeutics, Inc. | 50 | $45,377 |
| Hoffmann-la Roche Limited | 5 | $28,134 |
| Astrazeneca UK Limited | 1 | $13,146 |
| Roche Products Limited | 3 | $2,480 |
| Amgen(2 entities) | 34 | $930 |
| AstraZeneca(2 entities) | 20 | $593 |
| Fresenius USA Marketing, Inc. | 16 | $395 |
| Otsuka America Pharmaceutical, Inc. | 13 | $392 |
| Aurinia Pharma U.S., Inc. | 6 | $206 |
| Novo Nordisk | 4 | $161 |
| Calliditas Therapeutics US Inc. | 4 | $137 |
| Vifor Pharma, Inc. | 6 | $128 |
| Bayer | 6 | $114 |
| Mallinckrodt Enterprises LLC | 3 | $66 |
| Novartis | 4 | $62 |
| Apellis Pharmaceuticals, Inc. | 3 | $49 |
| Sanofi | 3 | $41 |
| Lilly USA, LLC | 2 | $39 |
| Nuwellis, Inc. | 2 | $31 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Scpharmaceuticals Inc. | 1 | $24 |
| OPKO Pharmaceuticals, LLC | 1 | $22 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Ardelyx, Inc. | 1 | $20 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$559,352 in reported general payments places this provider in the 95th percentile of 366 nephrology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Raleigh
- Jeffrey HoggardRaleigh$517K
- Sammy MoghaziRaleigh$56K
- Libbie McKenzieRaleigh$34K
- Daniel EdmonstonDurham$9.9M
- Gregory GreenwoodWinston-Salem$4.1M
- Barry FreedmanWinston Salem$3.5M
- Manuel MonteroNew Bern$2.5M
- Rekha JohnKinston$2.3M
- Nauman ShahidGreenville$2M
- Eric KirkWilmington$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.